Respiratory therapy

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Medical specialties, Anatomy, Cystic fibrosis, Lung disorders, Channelopathies, Respiratory therapy, Mucus, Nebulizer, Denufosol

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Since its inception in 2014, Nuance Pharma has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain and iron deficiency anemia.

Vapotherm to Host First Investor Day

Retrieved on: 
Wednesday, June 9, 2021
Biotechnology, Medical devices, Manufacturing, Other Manufacturing, Health, Medical specialties, Medicine, Health care, Medical emergencies, Respiratory therapy, Respiratory diseases, Diving medicine, Hypercapnia, Ventilator, Vapotherm, Respiratory therapist, Hypoxemia

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy systems.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.
  • Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/ .

ERT Announces Real-Time Coaching for Pulmonary Function Tests Performed in the Patient's Home

Retrieved on: 
Tuesday, June 8, 2021
Respiratory therapy, Clinical medicine, Health care, Medicine, ERT, Medical tests, Pulmonary function testing, Spirometry

PHILADELPHIA, June 8, 2021 /PRNewswire/ -- ERT , the global leader in data collection for clinical endpoints, today announced the launch of ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT).

Key Points: 
  • PHILADELPHIA, June 8, 2021 /PRNewswire/ -- ERT , the global leader in data collection for clinical endpoints, today announced the launch of ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT).
  • With iSpiro Virtual Visits, ERT delivers on its commitment to provide customer and patient-oriented innovations that facilitate decentralization.
  • "Performing spirometry correctly can be critical to the success of a drug approval," said Achim Schlke, Executive Vice President of ERT Respiratory Solutions.
  • By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly and with confidence.

Worldwide Commercial Aircraft Oxygen System Industry to 2025 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Air, Transport, Aerospace, Manufacturing, Chemistry, Physical sciences, Chemical elements, Oxygen, Respiratory therapy, Dosage forms, Industrial gases, Airliner

The "Global Commercial Aircraft Oxygen System Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Commercial Aircraft Oxygen System Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The publisher has been monitoring the commercial aircraft oxygen system market and it is poised to grow by $ 1.40 bn during 2021-2025 progressing at a CAGR of 12% during the forecast period.
  • The report on commercial aircraft oxygen system market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The commercial aircraft oxygen system market analysis includes type segment, component segment and geographical landscapes.

The Worldwide Medical Oxygen Concentrators & Oxygen Cylinders Industry is Expected to Reach $4.62 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, General Health, Chemistry, Physical sciences, Oxygen, Medicine, Industrial gases, Respiratory therapy, Dosage forms, Medical equipment, Oxygen concentrator, Oxygen therapy, Gas cylinder, Oxygen firebreak

The "Medical Oxygen Concentrators & Oxygen Cylinders Market Share, Size, Trends, Industry Analysis Report, By Product; By Technology; By End-users; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Oxygen Concentrators & Oxygen Cylinders Market Share, Size, Trends, Industry Analysis Report, By Product; By Technology; By End-users; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global medical oxygen concentrators & oxygen cylinders market size is expected to reach USD 4.62 billion by 2028 according to a new study.
  • Medical concentrators and cylinders are medical oxygen systems that are used to treat respiratory ailments and are commonly preferred by older patients who have limited mobility and rely on a consistent market supply.
  • The increasing market demand for medical concentrators and cylinders has resulted in the introduction and approval of new products in the market.

Expressing Gratitude to Respiratory Therapy Professionals

Retrieved on: 
Friday, June 4, 2021
Health care, Medical specialties, Health, Respiratory therapy, American Association for Respiratory Care, Respiratory therapist, Severe acute respiratory syndrome, Influenza A virus subtype H1N1, Health professional, College of Respiratory Therapists of Ontario, College and Association of Respiratory Therapists of Alberta

Since the days of 1918 Flu, through pulmonary tuberculosis, SARS and H1N1, and even Katrina, respiratory therapy has been there for them all.

Key Points: 
  • Since the days of 1918 Flu, through pulmonary tuberculosis, SARS and H1N1, and even Katrina, respiratory therapy has been there for them all.
  • Because of this, the American Association for Respiratory Care (AARC) developed a PSA video to highlight the profession and the work respiratory therapists do each day.
  • It also serves as a call to express our gratitude to these health care professionals, asking our community to take time to thank a respiratory therapist.
  • Like many health care professionals working on the front lines of the pandemic, respiratory therapists worked tirelessly and selflessly to help patients everywhere.

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

Retrieved on: 
Friday, June 4, 2021
Health, General Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Health, Respiratory therapy, Asthma, Placebo

Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of 2021.

Key Points: 
  • Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of 2021.
  • 4D pharma has demonstrated MRx-4DP0004s ability to reduce airway inflammation in a pre-clinical model of severe asthma.
  • The completion of enrollment in Part A of 4D pharmas asthma study is an important milestone for this program.
  • The first-in-human Phase I/II trial is a two part, multi-center, randomized, double-blind, placebo-controlled trial of MRx-4DP0004 in patients taking long-term medication for asthma.

Global Asthma Disease Analysis, Forecast and Market Analysis Report 2020: Treatments, Epidemiology, Marketed Drugs, Pipeline, Regulatory Events, Clinical Trials, Future Trends, Market Dynamics - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, Pharmaceutical, Respiratory diseases, Respiratory therapy, Asthma, Chronic lower respiratory diseases, Pulmonology, Cough, Bronchospasm, Obstructive lung disease

The "Disease Analysis: Asthma - Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Asthma - Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations.
  • The GINA treatment strategy released in 2019 included an important change disrupting a fundamental practice in mild asthma management.
  • Treatment with a short-acting beta 2 agonist (SABA) alone is no longer recommended for adults and adolescents with asthma.

Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®

Retrieved on: 
Thursday, June 3, 2021
Respiratory therapy, Ventilator, Intensive care medicine, Medicine, Health care, Ebola, Health

SAN DIEGO, June 3, 2021 /PRNewswire/ --Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier.

Key Points: 
  • SAN DIEGO, June 3, 2021 /PRNewswire/ --Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the publication of a pre-print manuscript highlighting two case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier.
  • The manuscript describes the use of the Hemopurifier for a total of nine sessions in two critically ill COVID-19 patients.
  • This patient received eight Hemopurifier treatments without complications and eventually was weaned from a ventilator and was discharged from the hospital.
  • "Given the success of the Hemopurifier as a treatment for Ebola patients, we remain optimistic about our ongoing work in the treatment of COVID-19 patients.

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Biology, Clinical medicine, Desmosine, Peptides, Protein structure, Respiratory physiology, Respiratory therapy, Spirometry, Biomarker

Interim data from the first seven patients in this open-label study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting in December 2020.

Key Points: 
  • Interim data from the first seven patients in this open-label study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting in December 2020.
  • In this phase 1 study, maximum-tolerated dose (MTD) was not reached and alvelestat was well tolerated.
  • Notably, two patients had improvement in forced expiratory volume in one second (FEV1) of 9%, and four patients experienced improvement in symptoms.
  • Subsequent analysis of the elastin breakdown biomarker desmosine, has recently been completed.